Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Reuteri for Androgenetic Alopecia
NCT07370519Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Countries
- 1
- Sponsor
- Shenzhen People's Hospital
- Modality
- Live Biotherapeutic Products
- Conditions
- androgenetic alopecia (AGA)
01
Overview
Phase 2, randomised, double-blind trial of lactobacillus reuteri in androgenetic alopecia (AGA) (4 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Hair Density at 12 months. Started Jan 2026; status: recruiting.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Test Group
Lactobacillus reuteri
Inactivated Control Group
Inactivated Lactobacillus reuteri
Positive Control Group
5% Minoxidil
Negative Control Group
Normal Saline
03
Who it enrols
Adults aged 18-60 with androgenetic alopecia (Norwood-Hamilton stage II-IV or Ludwig grade I-III) for less than 5 years, with no use of hair loss medications in the past 6 months, and no active skin diseases or uncontrolled diabetes/CVD.
04
Endpoints
Primary
Hair Density
Secondary
Hair Diameter
Beyond the preview
Go deeper on NCT07370519.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370519.